Evaluation of Liver Toxicity of 2-Methyl-3-Hydroxypyridin-4-one in Iron Overloaded Rats Hepatotoxicity of 2-methyl-3-hydroxypyridin-4-one
Iranian Journal of Pharmaceutical Sciences,
Vol. 2 No. 1 (2006),
15 January 2006
,
Page 35-40
https://doi.org/10.22037/ijps.v2.39600
Abstract
Hydroxypyridinone iron chelators are currently the main candidates for development of orally active iron chelating alternatives to desferrioxamine (DFO). In the present study, the relative efficacy and liver toxicity of a bidentate chelator, 2-methyl-3-hydroxypyridin-4-one (MHPO), was studied in iron overloaded rats and compared with those of DFO. For iron overloading, rats received i.p. injections of 100 mg/kg of iron-dextran twice a week for 4 consecutive weeks. They were
allowed for equilibration of iron after overloading for 15 days. Then the rats received i.p. injections of 200 mg/kg/day of either MHPO or DFO for 15 days. At the end of this period, blood samples were taken and the iron and ferritin concentrations, and the total iron binding capacity (TIBC) were determined. The activities of SGOT, SGPT and ALP were analyzed by standard colorimetric kits. Serum values for iron, TIBC and ferritin were shown to have no significant differences after the administration of either MHPO or DFO in treated rats. SGOT and SGPT values were significantly reduced after the administration of MHPO. DFO, however, was only able to reduce SGPT with the same dose. There were no significant differences between two chelators with regards to ALP. After the administration of MHPO, skin rashes were observed in a way that rats could not move. In conclusion, this study confirms that MHPO is at least as effectives as DFO at mobilizing iron, and reduces liver toxicity, however, with regard to other side effects such as its skin toxicity, further studies are required.
- Desferrioxamine
- Hepatotoxicity
- Hydroxypyridinones
- Iron overload
How to Cite
References
[2] Oliver NF, Nathan DG, Macmillan JH, Waynet A, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous thalassaemia. N Engl J Med 1994; 331: 574-8.
[3] Chen SH, Liang DC, Lin HC, Cheng SY, Chen LJ, Liu HC. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol 2005; 27: 651-3.
[4] Brittenham GM, Nathan DG, Oliveri NF, Pipaard MJ, Weatherall DJ. Deferiprone versus desferrioxamine in thalassaemia. Lancet 2003; 11: 183-4.
[5] Karimi M, Asadi-Pooya AA, Khademi B, Asadi-Pooya K, Yarmohammadi H. Evaluation of the incidence of sensorineural hearing loss in betathalassemia
major patients under regular chelation therapy with desferrioxamine. Acta Haematol 2002; 108: 79-83.
[6] Hidaiat RR, McLay IJ, Goode DH. Spearing RLEOG as a monitor of desferrioxamine retinal toxicity. Doc Ophthalmol 2004; 109: 273-8.
[7] Szwarcberg J, Mack G, Flament J. Ocular toxicity of deferoxamine: Description and analysis of three observations. J Fr Ophtalmol Jun 2002; 25: 609-14.
[8] Porter JB, Huehns R, Hider RC. The development of iron chelating drugs. Clin Haematol 1989; 2: 257-62.
[9] Moridiani MY, Tilbrook G, Khodr HH, Hider RC. Syntheses and physicochemical of 3-hydroxypyridin-4-ones. J Pharm Pharmacol 2002; 54: 349-64.
[10] Hider RC, Liu ZD. Emerging understanding of the advantage of small molecule such as hydroxypyridin ones in the treatment of iron overload. Cur Med Chem 2003; 10: 1051-64.
[11] Hider RC, Kontoghiorghes GJ, Silver J. Pharmaceutical compositions. UK Patent GB-2118176A; 1982.
[12] Olivieri NF, Brittenham GM. Iron chelating therapy and treatment of thalassaemia. Blood 1997; 89: 739-61.
[13] Taher A, Sheikh-Taha M, Sharara A, Koussa S, Fllis G, Dhillon AP, Hoffbrand AV. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta Haematol 2005; 114:146-9.
[14] Piga A, Roggero S, Vinciguerra T, Sacchetti L, Gallo V, Longo F. Deferiprone: New insight. Ann N Y Acad Sci 2005; 1054: 169-74.
[15] Meo A, Ruggeri A, La Rosa MA, Zanghi L, Kordes U, Ficher R. Long-term treatment with deferiprone in a L1 veteran. Eur J Haematol Jun 2005; 74: 523-5.
[16] Olivieri N. Long-term therapy with deferiprone.Acta Haematol 1996; 95: 37-48.
[17] Kowdley KV, Kaplan MN. Iron chelation therapywith oral deferiprone-toxicity or lack of efficacy. N Engl J Med 1998; 339: 468-9.
[18] Huehns ER, Porter JB, Hider RC. Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models. Hemoglobin 1988; 12: 593-600.
[19] Porter JB, Gyparki M, Huehns ER, Hider RC. The relationship between lipophilicity of hydroxypyridin-4-one iron chelators and cellular iron mobilization using hepatocyte culture model. Biochem Soc Trans 1986; 14: 1180.
[20] Saghaie L, Hider RC, Mostafavi DA. Comparison of automated continuous flow method with shakeflask method in determining partition coefficients of bidentate hydroxypyridinone ligands. Daru 2003; 11: 38-46.
[21] Haimovici R, Amico DJ, Gragoudas ES, Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002; 109:164-71.
[22] Porter JB, Jaswan MS, Huehns ER, East CA, Hazell JWP. Desferrioxamine ototoxity: Evaluation of risk factors in thalassaemia patients and guidelines for safe dosage. Br J Haematol1990; 73:403-9.
[23] Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 1990; 76: 2389-96.
[24] Porte JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC. Comparison of the sub-acute toxicity and efficacy of 3-hydroxy pyridine-4-one iron chelators in iron over load and non over loaded mice. Blood 1991; 78: 20-4
[25] Henderson AP, Moss DW. Enzymes. In: Tiets NW(editor). Fundamentals of clinical chemistry. 5th ed. Pheldelphia: WB Sunders, 2001; pp. 356–67.
[26] International committee for standardization in haematology: The measurement of iron and total iron binding capacity in serum. Br J Haematol 1978; 38: 281-90.
[27] Fairbanks VF, Klee GG. Ferritine in progress in clinical pathology. Vol. 8. New York: Grune and Stratton, 1981; pp. 175-203.
[28] Porter JB. Oral iron chelators, prospects for future development. Eur J Haematol 1988; 43: 271.
[29] Cerami A, Grady RW, Peterson CM, Bhargava K. The status of new iron chelators. Ann NY Acad Sci 1980; 344: 425.
[30] Peter H.H. Industrial aspects of iron chelators: Pharmaceutical applications. In: Spik G, Motereuil J, Crichton RR, Mazurier J (editors). Proteins of iron storage and transport. New York, Elsevier, 1985; p. 283.
- Abstract Viewed: 51 times
- IJPS_Volume 2_Issue 1_Pages 35-40 Downloaded: 12 times